The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.

TEXT Treatment patterns and real-world survival outcomes varied by race/ethnicity, socioeconomic status, and practice setting in a cohort of women treated ...

New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults ...

DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic TNBC Who Are Not Candidates ...

Add Yahoo as a preferred source to see more of our stories on Google. And now, a new study published in Nature has found that viral lung infections can awaken dormant breast cancer cells that have ...

HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

At Baylor Scott & White Health, a groundbreaking initiative is underway aiming to revolutionize early detection and intervention strategies for better breast cancer survivorship and beyond. Led by ...

Prior experience with the provocative relationship between specific genetic factors and radiation sensitivity led to the speculation that there may be a clinically relevant relationship between chest ...

Phase 3 trial data show datopotamab deruxtecan reduces the risk of disease progression or death in patients with metastatic TNBC.

Some recent studies from the University of Miami’s Sylvester Comprehensive Cancer Center suggests that women living near ...